Aerie Pharmaceuticals CEO discusses what's new in the pipeline
Aerie Pharmaceuticals (Nasdaq: AERI) cleared to begin clinical testing for dry eye treatment - Triangle Business Journal
Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma to Advance Its Dry Eye Program | World Pharma Today
AERIE PHARMACEUTICALS, INC. 10K 2021
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease | Business Wire
Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc. (Aerie Pharmace) Stock Price & News | AERI
Commercial Model Design And Execution EXEEVO • UBIQ
EX-99.1
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% | Business Wire
Glaucoma Physician - February 12, 2021
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions | Business Wire
Aerie Pharmaceuticals gets $88M upfront in licensing agreement with Santen - Triangle Business Journal
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
Is Aerie Pharmaceuticals Ireland Ltd. late reporting EU clinical trials?
Articles about Aerie Pharmaceuticals, Inc. | page 5
AERIE PHARMACEUTICALS, INC. NPS 2022
Aerie Pharmaceuticals Inc - Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before
Mitchell de Long on LinkedIn: Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer |…
